Precision Radiotherapy for Tumours Using Magnetic Resonance-guided Linear Accelerator (MR-Linac)

NCT06531681 · tracked via the Priya Life Science China tracker

Sponsor

The Second Affiliated Hospital of Hainan Medical University

Phase

Observational

Started

2023-08-19

Last updated

2025-02-13

Condition(s) studied

Overall Response RateOncologyRadiation ToxicityQuality of Life

Investigational drug(s) / intervention(s)

MR-Linac

MR-Linac: Radiation therapy with the MR-Linac

Study summary

Aim to observe the application of MR-Linac for precision radiotherapy of tumours, analyse its therapeutic effect, toxic and side effects,Characteristics of dosimetric parameters etc.

Eligibility

Sex

ALL

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: * Patients are undergoing or have undergone imaging or treatment at the MR linac; * Age 18-75 years, male or female; * ECOG score 0-2, life expectancy \> 6 months; * Patients provide written informed consent. Exclusion Criteria: * Contraindications to MRI, such as claustrophobia and metallic or electronic implants incompatible with MRI; * The presence of severe comorbidities that, in the opinion of the investigator, · preclude the toleration or completion of radiotherapy; * Acute inflammatory disease requiring systemic therapy; * The presence of active infectious disease; * Pregnant women, nursing mothers, and patients planning to have children during the study period.

Primary outcome measure(s)

overall response rate — 3months， 6months，12months，24months，36months，60months
The proportion of patients whose tumor volume reduction reached the predetermined value and maintained the minimum time limit requirement was the sum of CR (Complete Response) and PR (Partial Response) proportions.

Trial sites (1)

Facility	City	Region	Status
The Second Affiliated Hospital of Hainan Medical University	Haikou	China	Recruiting

More The Second Affiliated Hospital of Hainan Medical University trials in China

Comparison of the Therapeutic Effects of Methylprednisolone and Dexamethasone on Peritumoral Edema During Radiotherapy for Brain Metastases: Starting soon

A Study Investigating the Efficacy and Safety of the Combination of Iparomlimab and Tuvonralimab With or Without Chemotherapy in Second-line and Subsequent Treatments for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Recruiting

Topical Diclofenac for Prevention of Radiation-induced Dermatitis Recruiting

Hypofractionated Radiotherapy for Nasopharyngeal Carcinoma Recruiting

Other trials for the same condition

The Impact of Airway Allergic Diseases on Children's and Parents' Quality of Life Recruiting

Effect of Surgical Margin Width on Recurrence and Survival in Patients With Hepatic Oligometastasis of Colorectal Cancer Recruiting

Sentinel Lymph Node Biopsy Versus Pelvic Lymphadenectomy in Early-stage Cervical Cancer (PHENIX/CSEM 010) Active, not recruiting

The Impact of Socioeconomic Determinants on the Patient Reported Outcomes in Young Breast Cancer Patients After Breast Surgery Recruiting

Comparing Myopia Treatments in Youth: Defocus Spectacles, Glasses, and Ortho-K Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06531681 on ClinicalTrials.gov ↗ ← All trials in China